GUIDED THERAPEUTICS INC (GTHP) Form 10-Q — May 15, 2026
Guided Therapeutics reported a net loss of $500,000 for the three months ended March 31, 2026, with zero revenue generated from its LuViva cervical cancer detection device. The company ended the quarter with only $369,000 in cash and a working capital deficit of $5.1 million, signaling severe liquidity constraints. The filing includes explicit going-concern language, stating that substantial doubt exists about the company's ability to continue as a going concern. Management acknowledged that if sufficient capital cannot be raised, the company may be required to curtail operations, liquidate, or file for bankruptcy protection.
Key figures
- Revenue
- 0
- Cash Position
- 369000
- Shares Outstanding
- 96537349
- Warrants Outstanding
- 39793149
Price after filing
Close on the filing date to close N calendar days later (from $0.20). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.